nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—SLC22A5—dilated cardiomyopathy	0.026	1	CrCbGaD
Apraclonidine—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.011	0.0269	CcSEcCtD
Apraclonidine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00885	0.0217	CcSEcCtD
Apraclonidine—Malaise—Spironolactone—dilated cardiomyopathy	0.0086	0.0211	CcSEcCtD
Apraclonidine—Photophobia—Lisinopril—dilated cardiomyopathy	0.00836	0.0205	CcSEcCtD
Apraclonidine—Irritability—Furosemide—dilated cardiomyopathy	0.00822	0.0202	CcSEcCtD
Apraclonidine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00802	0.0197	CcSEcCtD
Apraclonidine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00697	0.0171	CcSEcCtD
Apraclonidine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00692	0.017	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00672	0.0165	CcSEcCtD
Apraclonidine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00641	0.0157	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00641	0.0157	CcSEcCtD
Apraclonidine—Face oedema—Lisinopril—dilated cardiomyopathy	0.00624	0.0153	CcSEcCtD
Apraclonidine—Irritability—Lisinopril—dilated cardiomyopathy	0.00617	0.0151	CcSEcCtD
Apraclonidine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00578	0.0142	CcSEcCtD
Apraclonidine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00574	0.0141	CcSEcCtD
Apraclonidine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00573	0.0141	CcSEcCtD
Apraclonidine—Asthma—Lisinopril—dilated cardiomyopathy	0.00559	0.0137	CcSEcCtD
Apraclonidine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00557	0.0137	CcSEcCtD
Apraclonidine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00551	0.0135	CcSEcCtD
Apraclonidine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00541	0.0133	CcSEcCtD
Apraclonidine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00533	0.0131	CcSEcCtD
Apraclonidine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00532	0.0131	CcSEcCtD
Apraclonidine—Erythema—Furosemide—dilated cardiomyopathy	0.00519	0.0127	CcSEcCtD
Apraclonidine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00515	0.0126	CcSEcCtD
Apraclonidine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00508	0.0125	CcSEcCtD
Apraclonidine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00495	0.0121	CcSEcCtD
Apraclonidine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0049	0.012	CcSEcCtD
Apraclonidine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00489	0.012	CcSEcCtD
Apraclonidine—Headache—Spironolactone—dilated cardiomyopathy	0.00488	0.012	CcSEcCtD
Apraclonidine—Nausea—Spironolactone—dilated cardiomyopathy	0.00462	0.0113	CcSEcCtD
Apraclonidine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00455	0.0112	CcSEcCtD
Apraclonidine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00448	0.011	CcSEcCtD
Apraclonidine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00444	0.0109	CcSEcCtD
Apraclonidine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00441	0.0108	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00439	0.0108	CcSEcCtD
Apraclonidine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00432	0.0106	CcSEcCtD
Apraclonidine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00415	0.0102	CcSEcCtD
Apraclonidine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00411	0.0101	CcSEcCtD
Apraclonidine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00406	0.00994	CcSEcCtD
Apraclonidine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00403	0.00988	CcSEcCtD
Apraclonidine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.004	0.00979	CcSEcCtD
Apraclonidine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00392	0.0096	CcSEcCtD
Apraclonidine—Erythema—Lisinopril—dilated cardiomyopathy	0.00389	0.00954	CcSEcCtD
Apraclonidine—Tension—Lisinopril—dilated cardiomyopathy	0.00382	0.00936	CcSEcCtD
Apraclonidine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00381	0.00934	CcSEcCtD
Apraclonidine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.0038	0.00932	CcSEcCtD
Apraclonidine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00378	0.00927	CcSEcCtD
Apraclonidine—Somnolence—Furosemide—dilated cardiomyopathy	0.00376	0.00923	CcSEcCtD
Apraclonidine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00367	0.00899	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00366	0.00896	CcSEcCtD
Apraclonidine—Fatigue—Furosemide—dilated cardiomyopathy	0.00365	0.00895	CcSEcCtD
Apraclonidine—Pain—Furosemide—dilated cardiomyopathy	0.00362	0.00888	CcSEcCtD
Apraclonidine—Constipation—Furosemide—dilated cardiomyopathy	0.00362	0.00888	CcSEcCtD
Apraclonidine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00361	0.00885	CcSEcCtD
Apraclonidine—Malaise—Lisinopril—dilated cardiomyopathy	0.00351	0.0086	CcSEcCtD
Apraclonidine—Syncope—Lisinopril—dilated cardiomyopathy	0.00349	0.00856	CcSEcCtD
Apraclonidine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00349	0.00855	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00346	0.00849	CcSEcCtD
Apraclonidine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00344	0.00843	CcSEcCtD
Apraclonidine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00335	0.0082	CcSEcCtD
Apraclonidine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00331	0.00812	CcSEcCtD
Apraclonidine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00331	0.00812	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00329	0.00807	CcSEcCtD
Apraclonidine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00327	0.00803	CcSEcCtD
Apraclonidine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00324	0.00794	CcSEcCtD
Apraclonidine—Oedema—Lisinopril—dilated cardiomyopathy	0.00318	0.00779	CcSEcCtD
Apraclonidine—Infection—Lisinopril—dilated cardiomyopathy	0.00316	0.00774	CcSEcCtD
Apraclonidine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00312	0.00765	CcSEcCtD
Apraclonidine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00309	0.00756	CcSEcCtD
Apraclonidine—Asthenia—Furosemide—dilated cardiomyopathy	0.00304	0.00745	CcSEcCtD
Apraclonidine—Pruritus—Furosemide—dilated cardiomyopathy	0.003	0.00734	CcSEcCtD
Apraclonidine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0029	0.0071	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00289	0.00709	CcSEcCtD
Apraclonidine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00287	0.00704	CcSEcCtD
Apraclonidine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00285	0.00699	CcSEcCtD
Apraclonidine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00283	0.00694	CcSEcCtD
Apraclonidine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00282	0.00692	CcSEcCtD
Apraclonidine—Dizziness—Furosemide—dilated cardiomyopathy	0.0028	0.00686	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00274	0.00672	CcSEcCtD
Apraclonidine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00274	0.00671	CcSEcCtD
Apraclonidine—Constipation—Lisinopril—dilated cardiomyopathy	0.00272	0.00666	CcSEcCtD
Apraclonidine—Pain—Lisinopril—dilated cardiomyopathy	0.00272	0.00666	CcSEcCtD
Apraclonidine—Vomiting—Furosemide—dilated cardiomyopathy	0.00269	0.0066	CcSEcCtD
Apraclonidine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00267	0.00654	CcSEcCtD
Apraclonidine—Headache—Furosemide—dilated cardiomyopathy	0.00265	0.0065	CcSEcCtD
Apraclonidine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00262	0.00642	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.0026	0.00637	CcSEcCtD
Apraclonidine—Nausea—Furosemide—dilated cardiomyopathy	0.00252	0.00616	CcSEcCtD
Apraclonidine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00251	0.00616	CcSEcCtD
Apraclonidine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00234	0.00574	CcSEcCtD
Apraclonidine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00228	0.00559	CcSEcCtD
Apraclonidine—Pruritus—Lisinopril—dilated cardiomyopathy	0.00225	0.00551	CcSEcCtD
Apraclonidine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00217	0.00533	CcSEcCtD
Apraclonidine—Dizziness—Lisinopril—dilated cardiomyopathy	0.0021	0.00515	CcSEcCtD
Apraclonidine—Vomiting—Lisinopril—dilated cardiomyopathy	0.00202	0.00495	CcSEcCtD
Apraclonidine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.002	0.00491	CcSEcCtD
Apraclonidine—Headache—Lisinopril—dilated cardiomyopathy	0.00199	0.00488	CcSEcCtD
Apraclonidine—ADRA2B—Hemostasis—ACTN2—dilated cardiomyopathy	0.00195	0.00344	CbGpPWpGaD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.00191	0.00337	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00189	0.00335	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00189	0.00334	CbGpPWpGaD
Apraclonidine—Nausea—Lisinopril—dilated cardiomyopathy	0.00189	0.00463	CcSEcCtD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00188	0.00332	CbGpPWpGaD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.00187	0.0033	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00182	0.00322	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ACTN2—dilated cardiomyopathy	0.00182	0.00322	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00176	0.0031	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00173	0.00306	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00173	0.00306	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TTN—dilated cardiomyopathy	0.0017	0.00301	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.0017	0.00301	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—VCL—dilated cardiomyopathy	0.00166	0.00293	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00165	0.00292	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00165	0.00292	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00165	0.00292	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00164	0.0029	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00162	0.00286	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00162	0.00286	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00161	0.00285	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00156	0.00276	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00156	0.00275	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—VCL—dilated cardiomyopathy	0.00155	0.00273	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00154	0.00272	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00154	0.00271	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00154	0.00271	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00151	0.00266	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00149	0.00263	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ACTN2—dilated cardiomyopathy	0.00148	0.00261	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00148	0.00261	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00147	0.0026	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00146	0.00258	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00145	0.00257	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00143	0.00252	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00142	0.0025	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00142	0.0025	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00138	0.00244	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00138	0.00244	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.00138	0.00243	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00133	0.00236	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00132	0.00233	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00132	0.00233	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00132	0.00233	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00132	0.00232	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00132	0.00232	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.0013	0.00229	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.00129	0.00227	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00127	0.00225	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00127	0.00224	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00126	0.00223	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VCL—dilated cardiomyopathy	0.00126	0.00222	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00125	0.0022	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00123	0.00218	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00123	0.00218	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00123	0.00217	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00122	0.00216	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.00121	0.00214	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00121	0.00213	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ANKRD1—dilated cardiomyopathy	0.00119	0.00211	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00119	0.0021	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00118	0.00209	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00118	0.00209	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00118	0.00209	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00118	0.00208	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00116	0.00204	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00115	0.00203	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TAZ—dilated cardiomyopathy	0.00112	0.00198	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00112	0.00198	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00111	0.00196	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.0011	0.00195	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00109	0.00192	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00108	0.0019	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00108	0.0019	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.00104	0.00184	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00103	0.00183	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00103	0.00182	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SDHA—dilated cardiomyopathy	0.00102	0.00179	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00102	0.00179	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00101	0.00179	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.001	0.00177	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.001	0.00177	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.001	0.00177	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000984	0.00174	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000971	0.00171	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ANKRD1—dilated cardiomyopathy	0.00097	0.00171	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000963	0.0017	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000959	0.0017	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000948	0.00168	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000938	0.00166	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000931	0.00165	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TAZ—dilated cardiomyopathy	0.000912	0.00161	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000902	0.00159	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.0009	0.00159	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000895	0.00158	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000876	0.00155	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.00086	0.00152	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ITGB1—dilated cardiomyopathy	0.000832	0.00147	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000829	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SDHA—dilated cardiomyopathy	0.000825	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000803	0.00142	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000786	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ITGB1—dilated cardiomyopathy	0.000777	0.00137	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00077	0.00136	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000766	0.00135	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000746	0.00132	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000746	0.00132	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000731	0.00129	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000718	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000714	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000712	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—CD36—dilated cardiomyopathy	0.000709	0.00125	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000697	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000697	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000694	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000677	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000677	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000672	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—RAC1—dilated cardiomyopathy	0.000669	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000667	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—CD36—dilated cardiomyopathy	0.000663	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000652	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000648	0.00114	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000633	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000633	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ITGB1—dilated cardiomyopathy	0.000631	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00063	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000627	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—RAC1—dilated cardiomyopathy	0.000624	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00061	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000609	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000609	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000588	0.00104	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000583	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000574	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00057	0.00101	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000566	0.001	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000566	0.001	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000566	0.001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000553	0.000977	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000553	0.000977	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000548	0.000969	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000544	0.000962	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000542	0.000958	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—CD36—dilated cardiomyopathy	0.000538	0.000951	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000536	0.000947	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000526	0.00093	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000521	0.00092	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000514	0.000909	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000514	0.000908	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000514	0.000908	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00051	0.0009	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000508	0.000898	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—RAC1—dilated cardiomyopathy	0.000507	0.000896	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000498	0.00088	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000494	0.000873	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000492	0.00087	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000487	0.00086	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000478	0.000844	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000468	0.000828	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000463	0.000818	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000462	0.000816	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000451	0.000796	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000444	0.000785	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—RAF1—dilated cardiomyopathy	0.000443	0.000783	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000435	0.000769	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000425	0.000752	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000422	0.000746	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000421	0.000744	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—RAF1—dilated cardiomyopathy	0.000414	0.000732	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000413	0.00073	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000404	0.000713	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000404	0.000713	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.0004	0.000707	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.0004	0.000707	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000395	0.000698	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000395	0.000697	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000384	0.000678	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000377	0.000666	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000375	0.000662	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000374	0.00066	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000374	0.00066	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000372	0.000657	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000368	0.00065	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000367	0.000648	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00036	0.000637	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000358	0.000633	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000348	0.000614	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000345	0.00061	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000342	0.000605	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000342	0.000604	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000337	0.000595	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—RAF1—dilated cardiomyopathy	0.000336	0.000594	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00033	0.000582	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000327	0.000577	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000327	0.000577	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000321	0.000566	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000313	0.000554	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000308	0.000544	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000306	0.000541	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000304	0.000537	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000304	0.000536	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000304	0.000536	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000299	0.000529	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000294	0.00052	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000292	0.000516	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000291	0.000514	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000287	0.000508	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000282	0.000499	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000278	0.000491	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	0.000276	0.000487	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000273	0.000483	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000273	0.000482	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	0.000269	0.000475	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000254	0.000449	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000251	0.000444	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000251	0.000443	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	0.000242	0.000427	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000238	0.000421	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000238	0.00042	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000234	0.000414	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000233	0.000413	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000227	0.0004	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	0.000224	0.000396	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000222	0.000391	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	0.000218	0.000386	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	0.000217	0.000383	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000212	0.000374	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000208	0.000367	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000205	0.000362	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	0.000202	0.000357	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	0.000196	0.000347	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000193	0.000341	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.00019	0.000336	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000185	0.000327	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000177	0.000312	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000174	0.000308	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000172	0.000304	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000164	0.00029	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000163	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	0.00015	0.000266	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000142	0.000252	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	0.00014	0.000248	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000132	0.000234	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000123	0.000217	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000114	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000103	0.000182	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	9.63e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	8.42e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	7.82e-05	0.000138	CbGpPWpGaD
